From MDD to MDR: Why Europe Rewrote the Rules for Medical Devices

EU MDR 2017/745 · Regulation (EU) 2023/607 · Regulation (EU) 2024/1860

For decades, the Medical Device Directive (MDD, Directive 93/42/EEC) formed the foundation for how medical devices were developed, tested and placed on the market in Europe. Since 26 May 2021, it is history. It has been replaced by the Medical Device Regulation (MDR, Regulation (EU) 2017/745) — a significantly stricter, more comprehensive and directly binding regulatory framework.

Why this change? And why now? Three factors explain the transition better than any single one: lost trust, rules lagging behind technology and a legal patchwork that could not continue as it was.

1. Lost Trust: Scandals as a Wake-Up Call

The MDD dates from 1993. It was certainly modern for its time — but it relied heavily on manufacturer self-responsibility and comparatively lean oversight by Notified Bodies.

This architecture came under massive pressure over the last decade:

• The PIP scandal (2010): French manufacturer Poly Implant Prothèse had for years produced breast implants using untested industrial silicone instead of medical-grade silicone. Hundreds of thousands of women worldwide were affected. The case showed that audits relying solely on documentation could not uncover systematic fraud.
• Metal-on-metal hip implants: Several models had to be recalled after thousands of revision surgeries. Patients suffered from metal debris migrating into the surrounding tissue.

The message to EU legislators was clear: a one-time certification at the outset is not enough. What is needed is lifecycle-accompanying oversight, stricter clinical evidence and tighter supervision of Notified Bodies.

2. Technology Moved Faster Than the Rules

The MDD was written when software was still an auxiliary tool — not a medical device in its own right. But during the 2010s the picture changed completely:

• Apps diagnose skin lesions.
• Algorithms analyse ECGs.
• Implants communicate wirelessly with cloud platforms.
• Combination products merge drug and device components.

The old MDD classification rules were no longer adequate for this reality. Many products that today fall into class IIa or IIb would have been classified as low-risk under the MDD — including standalone software that directly drives therapy decisions. Rule 11 of the MDR explicitly closes this gap and classifies medical software significantly higher.

3. From Patchwork to a Uniform Framework: Directive vs. Regulation

A frequently underestimated point is a legal one:

• The MDD was a Directive. Every Member State had to transpose it into national law — which led to 27 slightly different interpretations, forms and obligations.
• The MDR is a Regulation. It applies directly and identically in all EU Member States, without passing through national legislation.

This not only reduces bureaucratic friction but also closes loopholes: a manufacturer that could certify a product in a country applying the Directive leniently thereby gained de facto access to the entire Single Market. This "forum shopping" becomes considerably harder under the MDR.

4. What the MDR Changes in Practice

The Regulation pursues a single, overarching objective: greater safety for patients throughout the entire lifecycle of a product. This translates into a range of concrete changes:

In addition, legal responsibility has been distributed across the entire supply chain: not only manufacturers but also importers, distributors and authorised representatives now have explicit obligations.

5. The Timeline — and Why It Was Postponed Several Times

1. April 2017: MDR adopted by the European Parliament and Council
2. 25 May 2017: Entry into force
3. 26 May 2020: Originally planned date of application — postponed to 2021 due to the COVID-19 pandemic (Regulation (EU) 2020/561)
4. 26 May 2021: MDR becomes mandatorily applicable
5. March 2023: Regulation (EU) 2023/607 extends the transitional periods in a staggered manner until 31 December 2027 (class III and implantable IIb) and until 31 December 2028 (class IIa, non-implantable IIb, Is/Im/Ir); at the same time the sell-off deadline is removed
6. June 2024: Regulation (EU) 2024/1860 governs, among other things, the phased introduction of EUDAMED

These extensions are not a retreat. They are a response to a very real bottleneck: too few Notified Bodies, too many legacy products requiring recertification — and the European Commission's concern that important medical devices would simply disappear from the market without an extension.

The conditions for the extension are strict: manufacturers must have an MDR-compliant quality management system in place by 26 May 2024 and must have submitted a formal application to a Notified Body, and must be able to present a signed contract by 26 September 2024.

Conclusion: Not a Bureaucratic Burden, but a Systemic Shift

The MDR is uncomfortable for many manufacturers — particularly for smaller companies that feel the documentary and clinical burden. But it is not a regulatory whim. It is the direct response to concrete problems: scandals that cost patients their lives. Technologies that reached the market without an appropriate framework. And a Single Market that was never truly uniform without uniform rules.

Anyone developing medical devices today operates in an environment where safety, transparency and clinical evidence are no longer negotiable. That is demanding. But it is also the reason why the next generation of medical innovations stands on a significantly more solid foundation than the previous one.

In the next article we will look at what the MDR means in practice for the classification of medical devices — and why Rule 11 (software) has become the single biggest change for many manufacturers.